---
title: "CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290360834.md"
description: "CAMP4 Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On June 15, 2026, the company granted non-qualified stock options for 39,000 shares to three new employees as joining incentives. CAMP4 is a Cambridge-based biopharmaceutical firm developing RNA-targeting therapeutics for genetic diseases."
datetime: "2026-06-21T22:44:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290360834.md)
  - [en](https://longbridge.com/en/news/290360834.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290360834.md)
generator: "portal-rs"
---

# CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics Corporation, a biopharmaceutical company listed on Nasdaq under the ticker symbol CAMP, based in Cambridge, Massachusetts, announced today that on June 15, 2026, they granted non-qualified stock options for the purchase of a total of 39,000 shares of the company's common stock. These stock options were given to three new employees as inducements for joining the company. The goal of CAMP4 is to develop RNA-targeting therapeutics to increase gene expression, aiming to restore healthy protein levels for the treatment of various genetic diseases. This action was taken in compliance with Nasdaq Listing Rule 5635(c)(4).

### Related Stocks

- [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md)

## Related News & Research

- [Camp4 Therapeutics director Andrew J. Schwab disposes of USD 879,374 in common shares](https://longbridge.com/en/news/296653253.md)
- [CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells 45,147 Shares](https://longbridge.com/en/news/296653561.md)
- [Camp4 Therapeutics CSO Daniel Tardiff disposes of 1,738 common shares worth $8,272.88](https://longbridge.com/en/news/296415836.md)
- [CAMP4 Therapeutics Q2 loss per share misses estimates on non-cash derivative charge](https://longbridge.com/en/news/295841350.md)
- [Camp4 Therapeutics CEO Josh Mandel-Brehm acquires 6,551 common shares for $10,809.15](https://longbridge.com/en/news/295017282.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**